Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Opus Genetics ( (IRD) ).
On September 30, 2025, Opus Genetics announced positive results from its Phase 1/2 clinical trial of OPGx-LCA5, a gene therapy for Leber congenital amaurosis type 5. The trial showed that the therapy was well tolerated in both pediatric and adult participants, with no serious adverse events. Pediatric participants demonstrated significant improvements in visual function, and adult participants maintained visual acuity improvements for 18 months. The company plans to meet with the FDA in the fourth quarter of 2025 to discuss these promising results and future steps for the program.
The most recent analyst rating on (IRD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. The company’s pipeline includes AAV-based gene therapies targeting conditions such as Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Opus Genetics is headquartered in Research Triangle Park, NC.
Average Trading Volume: 260,485
Technical Sentiment Signal: Buy
Current Market Cap: $107.2M
Find detailed analytics on IRD stock on TipRanks’ Stock Analysis page.